Peringatan Keamanan

Kidney damage, fall in the number of white blood cells, decreased platelets

Cidofovir

DB00369

small molecule approved

Deskripsi

Cidofovir is an injectable antiviral medication employed in the treatment of cytomegalovirus (CMV) retinitis in patients diagnosed with AIDS. It suppresses CMV replication through selective inhibition of viral DNA synthesis.FDA label It was manufactured by Gilead and initially approved by the FDA in 1996, but has since been discontinued.L6223

Struktur Molekul 2D

Berat 279.187
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) 2.4 to 3.2 hours
Volume Distribusi * 537 ± 126 mL/kg [VISTIDE ADMINISTERED WITHOUT PROBENECID] * 410 ± 102 mL/kg [VISTIDE ADMINISTERED WITH PROBENECID]
Klirens (Clearance) * 179 +/- 23.1 mL/min/1.73 m2 [WITHOUT PROBENECID] * 148 +/- 38.8 mL/min/1.73 m2 [WITH PROBENECID]

Absorpsi

100%

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

802 Data
Foscarnet The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Foscarnet.
Mannitol The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Cidofovir.
Tenofovir disoproxil Cidofovir may increase the nephrotoxic activities of Tenofovir disoproxil.
Tenofovir alafenamide The serum concentration of Tenofovir alafenamide can be increased when it is combined with Cidofovir.
Tenofovir Cidofovir may increase the nephrotoxic activities of Tenofovir.
Triamterene The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Triamterene.
Etacrynic acid The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Etacrynic acid.
Hydrochlorothiazide The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Hydrochlorothiazide.
Cyclosporine The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cidofovir.
Icosapent The risk or severity of nephrotoxicity can be increased when Icosapent is combined with Cidofovir.
Cefotiam The risk or severity of nephrotoxicity can be increased when Cefotiam is combined with Cidofovir.
Mesalazine The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Cidofovir.
Cefmenoxime The risk or severity of nephrotoxicity can be increased when Cefmenoxime is combined with Cidofovir.
Cefmetazole The risk or severity of nephrotoxicity can be increased when Cefmetazole is combined with Cidofovir.
Indomethacin The risk or severity of nephrotoxicity can be increased when Indomethacin is combined with Cidofovir.
Ceftazidime The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Ceftazidime.
Piroxicam The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Piroxicam.
Methotrexate The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Methotrexate.
Cephalexin The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Cephalexin.
Valaciclovir The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Valaciclovir.
Furosemide The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Furosemide.
Flurbiprofen The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Flurbiprofen.
Etodolac The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Etodolac.
Acyclovir The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Acyclovir.
Cefaclor The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Cefaclor.
Diflunisal The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Diflunisal.
Bumetanide The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Bumetanide.
Meclofenamic acid The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Meclofenamic acid.
Acetylsalicylic acid The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Acetylsalicylic acid.
Carboplatin The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Carboplatin.
Oxaprozin The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Oxaprozin.
Ketoprofen The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Ketoprofen.
Ibuprofen The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Ibuprofen.
Cefadroxil The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Cefadroxil.
Ceftriaxone The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Ceftriaxone.
Cefotetan The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Cefotetan.
Cefradine The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Cefradine.
Ceftibuten The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Ceftibuten.
Aceclofenac The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Aceclofenac.
Benzydamine The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Benzydamine.
Dexketoprofen The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Dexketoprofen.
Propacetamol The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Propacetamol.
Cefroxadine The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Cefroxadine.
Alclofenac The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Alclofenac.
Cefpiramide The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Cefpiramide.
Loracarbef The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Loracarbef.
Cefalotin The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Cefalotin.
Nabumetone The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Nabumetone.
Ketorolac The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Ketorolac.
Tenoxicam The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Tenoxicam.
Celecoxib The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Celecoxib.
Cefotaxime The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Cefotaxime.
Tolmetin The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Tolmetin.
Rofecoxib The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Rofecoxib.
Fenoprofen The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Fenoprofen.
Valdecoxib The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Valdecoxib.
Diclofenac The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Diclofenac.
Sulindac The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Sulindac.
Bacitracin The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Bacitracin.
Amphotericin B The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Amphotericin B.
Cephaloglycin The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Cephaloglycin.
Adefovir dipivoxil The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Adefovir dipivoxil.
Pentamidine The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Pentamidine.
Mefenamic acid The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Mefenamic acid.
Naproxen The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Naproxen.
Sulfasalazine The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Sulfasalazine.
Phenylbutazone The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Phenylbutazone.
Meloxicam The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Meloxicam.
Carprofen The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Carprofen.
Tacrolimus The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Tacrolimus.
Ceforanide The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Ceforanide.
Salicylic acid The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Salicylic acid.
Balsalazide The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Balsalazide.
Cefditoren The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Cefditoren.
Atazanavir The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Atazanavir.
Colistimethate The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Colistimethate.
Cefuroxime The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Cefuroxime.
Cefapirin The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Cefapirin.
Cefprozil The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Cefprozil.
Olsalazine The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Olsalazine.
Lumiracoxib The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Lumiracoxib.
Cefamandole The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Cefamandole.
Cefazolin The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Cefazolin.
Cefonicid The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Cefonicid.
Cefoperazone The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Cefoperazone.
Cefoxitin The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Cefoxitin.
Ceftizoxime The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Ceftizoxime.
Magnesium salicylate The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Magnesium salicylate.
Salsalate The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Salsalate.
Choline magnesium trisalicylate The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Choline magnesium trisalicylate.
Cefepime The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Cefepime.
Cefacetrile The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Cefacetrile.
Cefpodoxime The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Cefpodoxime.
Antrafenine The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Antrafenine.
Aminophenazone The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Aminophenazone.
Antipyrine The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Antipyrine.
Tiaprofenic acid The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Tiaprofenic acid.
Lopinavir The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Lopinavir.
Etoricoxib The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Etoricoxib.
Hydrolyzed Cephalothin The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Hydrolyzed Cephalothin.

Target Protein

DNA polymerase catalytic subunit
DNA polymerase catalytic subunit UL54

Referensi & Sumber

Contoh Produk & Brand

Produk: 5 • International brands: 0
Produk
  • Cidofovir
    Injection, solution • 75 mg/1mL • Intravenous • US • Generic • Approved
  • Cidofovir Dihydrate
    Injection, solution • 375 mg/5mL • Intravenous • US • Generic • Approved
  • Mar-cidofovir
    Solution • 375 mg / 5 mL • Intravenous • Canada • Generic • Approved
  • Vistide
    Injection • 75 mg/1mL • Intravenous • US • Approved
  • Vistide
    Injection, solution, concentrate • 75 mg/ml • Intravenous • EU

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul